Reaction
Device Power Source Issue reporting signals
As of the last recalculation, Device Power Source Issue appears in 2,824 FAERS reports alongside 39 co-occurring drug terms. The strongest observed disproportionality signal is SOMATROPIN (PRR 348.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Somatropin | 1,561 | 348.9 | 356.5 |
| Pegfilgrastim | 486 | 43.6 | 43.8 |
| Ketoprofen | 69 | 39.7 | 39.9 |
| Amitriptyline Hydrochloride | 64 | 27.5 | 27.6 |
| Treprostinil | 342 | 22.7 | 22.8 |
| 0Xygen | 143 | 22.5 | 22.5 |
| Oxygen | 143 | 22.5 | 22.5 |
| Clonidine | 85 | 12.6 | 12.6 |
| Sildenafil | 89 | 11.7 | 11.7 |
| Cetirizine Hcl | 14 | 11.3 | 11.3 |
| Sildenafil Powder, | 50 | 10.5 | 10.5 |
| Sodium Chloride Tablet | 96 | 9.9 | 9.9 |
| Sodium Chloride Tablets | 96 | 9.9 | 9.9 |
| Macitentan | 89 | 9.7 | 9.8 |
| Lidocaine Hydrochloride | 77 | 9.7 | 9.7 |
| Sodium Chloride | 96 | 9.2 | 9.2 |
| Riociguat | 40 | 9.2 | 9.2 |
| Metolazone | 12 | 7.9 | 7.9 |
| Bupivacaine | 9 | 7.1 | 7.1 |
| Amantadine | 14 | 6.7 | 6.7 |
| Torsemide | 29 | 6.5 | 6.5 |
| Tadalafil | 86 | 6.5 | 6.5 |
| Carbidopa And Levodopa | 41 | 6.4 | 6.5 |
| Interferon Beta-1B | 16 | 6.2 | 6.2 |
| Bumetanide | 21 | 5.9 | 5.9 |
| Sildenafil Citrate | 98 | 5.8 | 5.8 |
| Cyclobenzaprine Hydrochloride | 7 | 5.8 | 5.8 |
| Benzonatate | 11 | 4.9 | 4.9 |
| Rotigotine | 9 | 4.6 | 4.6 |
| Hydroxyzine Hydrochloride | 8 | 4.5 | 4.5 |
| Hydroxyzine Hydrochloride Oral | 8 | 4.5 | 4.5 |
| Selexipag | 15 | 4.3 | 4.3 |
| Rasagiline Mesylate | 6 | 4.0 | 4.0 |
| Tiotropium Bromide Inhalation Spray | 6 | 4.0 | 4.0 |
| Ambrisentan | 60 | 3.6 | 3.6 |
| Nintedanib | 12 | 2.8 | 2.8 |
| Dofetilide | 4 | 2.8 | 2.8 |
| Sevelamer Carbonate | 4 | 2.6 | 2.6 |
| Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate | 14 | 2.5 | 2.5 |